A 6 Months NIS to Evaluate the Use of Rescue Medication and Quality of Life in Adult Asthmatic Subjects Treated With Symbicort® SMART®
NCT ID: NCT00884689
Last Updated: 2011-03-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
500 participants
OBSERVATIONAL
2009-04-30
2010-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Asthma patient with specific treatment
No interventions assigned to this group
2
Asthma patient on different specific treatment compared to the other group
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients being prescribed either Symbicort SMART or a free combination of ICS and LABA with SABA as rescue inhaler and being on that treatment for at least 3 month.
* A history (documented in the patient's file) of at least one severe asthma exacerbation within 24 months prior to visit 1 but not within the last 30 days prior to Visit 1.
* A severe asthma exacerbation is defined as a deterioration of asthma leading to at least one of the following:
* Oral/systemic GCS treatment due to asthma for at least 3 days
* Unscheduled health-care visit due to asthmaHospitalization or emergency room visit because of asthma requiring treatment with oral/systemic GCS
Exclusion Criteria
* Use of ß-blocking agents
* Respiratory infection affecting the asthma, as judged by the investigator, within 30 days prior to visit 1.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ClinResearch, GmbH
OTHER
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Vice President Medical
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kai Richter, MD
Role: STUDY_DIRECTOR
AstraZeneca
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Aschaffenburg, , Germany
Research Site
Bad Lippspringe, , Germany
Research Site
Bad Sassendorf, , Germany
Research Site
Bergkamen, , Germany
Research Site
Berlin, , Germany
Research Site
Bochum, , Germany
Research Site
Bonn, , Germany
Research Site
Braunschweig, , Germany
Research Site
Buchholz, , Germany
Research Site
Chemnitz, , Germany
Research Site
Coswig, , Germany
Research Site
Cottbus, , Germany
Research Site
Dortmund, , Germany
Research Site
Dresden, , Germany
Research Site
Düsseldorf, , Germany
Research Site
Frankfurt, , Germany
Research Site
Fürth, , Germany
Research Site
Gelsenkirchen, , Germany
Research Site
Gütersloh, , Germany
Research Site
Halle, , Germany
Research Site
Hamburg, , Germany
Research Site
Ketzin, , Germany
Research Site
Köthen, , Germany
Research Site
Leipzig, , Germany
Research Site
Löhne, , Germany
Research Site
Lübeck, , Germany
Research Site
Lüdenscheid, , Germany
Research Site
Marburg, , Germany
Research Site
Marl, , Germany
Research Site
Mittelbach, , Germany
Research Site
Mühlhausen, , Germany
Research Site
Mülheim, , Germany
Research Site
München, , Germany
Research Site
Oschersleben, , Germany
Research Site
Potsdam, , Germany
Research Site
Remscheid, , Germany
Research Site
Saarlouis, , Germany
Research Site
Schwetzingen, , Germany
Research Site
Steinhagen, , Germany
Research Site
Stockach, , Germany
Research Site
Wedel, , Germany
Research Site
Wesseling, , Germany
Research Site
Weyhe, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIS-RDE-SYM-2009/1
Identifier Type: -
Identifier Source: org_study_id